Skip to content

SPP closes at 5pm AWST Wed 25th Nov 2026  Learn more    

Proteomics International signs deal to launch PromarkerD test for diabetic kidney disease in USA

Proteomics International Ltd (Proteomics International; ASX: PIQ) has signed the first licence agreement for its world-leading PromarkerD predictive test for diabetic kidney disease in the United States, creating a partnership with US-based precision medicine and diagnostic services laboratory PrismHealthDx, Inc. (PHDx).

Media release